The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Increased NADP reduced (NADPH) oxidase 4 (Nox4) and reduced expression of the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) contribute to hypoxia-induced pulmonary hypertension (PH). To examine the role of Nox4 activity in pulmonary vascular cell proliferation and PH, the current study used a novel Nox4 inhibitor, GKT137831, in hypoxia-exposed human pulmonary artery endothelial or smooth muscle cells (HPAECs or HPASMCs) in vitro and in hypoxia-treated mice in vivo. HPAECs or HPASMCs were exposed to normoxia or hypoxia (1% O(2)) for 72 hours with or without GKT137831. Cell proliferation and Nox4, PPARγ, and transforming growth factor (TGF)β1 expression were measured. C57Bl/6 mice were exposed to normoxia or hypoxia (10% O(2)) for 3 weeks with or without GKT137831 treatment during the final 10 days of exposure. Lung PPARγ and TGF-β1 expression, right ventricular hypertrophy (RVH), right ventricular systolic pressure (RVSP), and pulmonary vascular remodeling were measured. GKT137831 attenuated hypoxia-induced H(2)O(2) release, proliferation, and TGF-β1 expression and blunted reductions in PPARγ in HPAECs and HPASMCs in vitro. In vivo GKT137831 inhibited hypoxia-induced increases in TGF-β1 and reductions in PPARγ expression and attenuated RVH and pulmonary artery wall thickness but not increases in RVSP or muscularization of small arterioles. This study shows that Nox4 plays a critical role in modulating proliferative responses of pulmonary vascular wall cells. Targeting Nox4 with GKT137831 provides a novel strategy to attenuate hypoxia-induced alterations in pulmonary vascular wall cells that contribute to vascular remodeling and RVH, key features involved in PH pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, so far no direct antioxidative side effects of GKT 137831 were reported [392] highlighting this substance as the most promising inhibitor for Nox enzymes not only in vitro but also in vivo [94,409,411,412,413,414].”
From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [413]
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989 · cited 6×
“NADPH oxidases catalyze the reduction of molecular oxygen to generate superoxide (O2 ), hydrogen peroxide (H2O2), or secondary oxidants (7).”
BackgroundInfluentialHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Nihon-Kokyuki-Gakkai (2011) · Cited by 1,301
Vascular NAD(P)H oxidases: specific features, expression, and regulation
Lassègue, B., & Clempus, R. E. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00758.2002 · Cited by 1,032 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundGriendling, K. K., Sorescu, D., Lassègue, B., & Ushio-Fukai, M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2175 · Cited by 955 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundSuperoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847 · cited 5×
“As the predominant Nox isoform expressed in VSMCs and ECs, Nox4 constitutes an attractive target for PH therapy.”
BackgroundInfluentialNox proteins in signal transduction
Brown, D. I., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 832 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundCucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundApocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100214 · Cited by 735 · cited 1×
“Apocynin also functions as an antioxidant in vascular ECs and SMCs, cells that lack the myeloperoxidase activity necessary for apocynin activation (37).”
Background
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Functions of ROS in Macrophages and Antimicrobial Immunity
Herb, M., & Schramm, M. (2021) · Antioxidants · doi:10.3390/antiox10020313 · Cited by 633
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
“Another role for NOX4 in pulmonary vessels was suggested, as GKT137831 treatment prevented hypoxia-induced right ventricle hypertrophy, thereby attenuating pulmonary hypertension (65).”
BackgroundNADPH Oxidases in Vascular Pathology
Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., & Guzik, T. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5607 · Cited by 452
Pulmonary Arterial Hypertension: The Clinical Syndrome
Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014) · Circulation Research · doi:10.1161/circresaha.115.301146 · Cited by 402
“RNA–mediated knockdown of Nox4 or Nox4 inhibitor GKT137831 attenuated vascular remodeling.(104,105) A cross-”
Background
Metadata
- Authors
- Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M.
- Affiliations
- Emory University (US)
- Genkyotex (Switzerland) (CH)
- Corresponding author
- Hart, C. Michael
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-01
- Volume
- 47
- Issue
- 5
- Pages
- 718-726
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC3547100
- OpenAlex
- W1990038383
- Cited by
- 146
- References
- 50
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 14 · 2018: 18 · 2017: 19 · 2016: 16 · 2015: 11 · 2014: 14 · 2013: 13
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (NHLBI T32, HL081064, HL 60917)
- National Heart, Lung, and Blood Institute (HL-60917, HL-081064, T32HL076118, P01HL081064, R01HL102167, R01HL060917)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074518)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- NOX4, GKT137831, NADPH oxidase inhibitors, hypoxia, pulmonary hypertension, PPARγ, TGF-β1, pulmonary artery endothelial cells, pulmonary artery smooth muscle cells, right ventricular hypertrophy, pulmonary vascular remodeling, hydrogen peroxide
- MeSH terms
- NADPH Oxidase 4, Rosiglitazone, Animals, Cells, Cultured, Endothelium, Vascular, Humans, Hydrogen Peroxide, Hypertension, Pulmonary, Lung, Mice, Inbred C57BL, Pulmonary Artery, Pyrazoles, Pyridines, Pyridones, Cell Hypoxia, Gene Expression, Proliferating Cell Nuclear Antigen, NADPH Oxidases, Ventricular Remodeling, Myocytes, Smooth Muscle, RNA Interference, Endothelial Cells, Thiazolidinediones, Pyrazolones, PPAR gamma, Cell Proliferation, Mice, Transforming Growth Factor beta1, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation. https://app.cochat.ai/papers/10.1165/rcmb.2011-0418oc
- The paper
- Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012). The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2011-0418oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.